Cargando…
Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia
Evidence from genetic disorders of CNP signalling suggests that plasma concentrations of CNP are subject to feedback regulation. In subjects with Achondroplasia (Ach), CNP intracellular activity is suppressed and plasma concentrations are raised but the therapeutic impact of exogenous CNP agonists o...
Autores principales: | Prickett, Timothy C. R., Espiner, Eric A., Irving, Melita, Bacino, Carlos, Phillips, John A., Savarirayan, Ravi, Day, Jonathan R. S., Fisheleva, Elena, Larimore, Kevin, Chan, Ming Liang, Jeha, George S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688426/ https://www.ncbi.nlm.nih.gov/pubmed/34930956 http://dx.doi.org/10.1038/s41598-021-03593-1 |
Ejemplares similares
-
Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
por: Chan, Ming Liang, et al.
Publicado: (2021) -
LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2022) -
SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2020) -
Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery
por: Savarirayan, Ravi, et al.
Publicado: (2021) -
Persistent and Stable Growth Promoting Effects of Vosoritide in Children With Achondroplasia for up to 2 Years: Results From the Ongoing Phase 3 Extension Study
por: Savarirayan, Ravi, et al.
Publicado: (2021)